A Post Marketing Safety Study of Lasmiditan (REYVOW®) to describe the use in pregnant women and pregnancy outcomes using the Japan Medical Data Center Database (H8H-MC-B011)

ENCePP Code of conduct

No

Data sources

• Data source(s), other:
  JMDC Japan
• Data sources (types):
  Administrative healthcare records (e.g., claims)

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No